**1. Introduction**

AIDS (Acquired immune deficiency syndrome) is the major cause of death which leads to pandemic worldwide. In today's scenario combination of Nucleoside reverse transcriptase inhibitors (NRTI), Non nucleoside reverse transcriptase inhibitors (NNRTI) and Protease inhibitors (PI). Highly active antiretroviral therapy (HAART) also called as anti retroviral therapy which is a combination of two or more combination of antiviral drugs become unsuccessful because of mutational change and virus getting resistant against anti viral drugs. Non nucleoside reverse transcriptase Inhibitors (NNRTI) binds to specific active site of reverse transcriptase of HIV are the important cascade of anti HIV-1 drugs mechanism. Molecular modeling studies of HIV enzyme complexes and chemical generation of second and third generation of

NNRTI's led to higher specificity of NNRTI's against HIV-1 and leads to major discovery in the generation of anti-viral drugs [1].

Non nucleoside reverse transcriptase inhibitor binding pocket were found to play an important role in binding site with drugs and found less prone against mutation. Here we also describe the chronological history of non nucleoside reverse transcriptase inhibitors development and basically focused on small molecules belonging to NNRTI class against AIDS management therapy [2].

In this review the chronological advancement of non nucleoside reverse transcriptase inhibitors and their belongings to NNRTI class in the management of drugs used in treatment of AIDS have been focused. The generation of resistance against NNRTI drugs and pharmacokinetic problems are the serious concern in management therapy.
